Charles Schwab
LUMO

Charles Schwab’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Charles Schwab’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,411
Closed -$94K – 3274
2019
Q1 		$94K Hold
5,411
– – ﹤0.01% 3094
2018
Q4 		$75K Hold
5,411
– – ﹤0.01% 3110
2018
Q3 		$117K Sell
5,411
-8,446
-61% -$257K ﹤0.01% 3109
2018
Q2 		$594K Buy
13,857
+458
+3% +$21K ﹤0.01% 2756
2018
Q1 		$875K Buy
13,399
+2,183
+19% +$155K ﹤0.01% 2562
2017
Q4 		$819K Buy
11,216
+2,079
+23% +$172K ﹤0.01% 2577
2017
Q3 		$838K Buy
9,137
+488
+6% +$37.4K ﹤0.01% 2554
2017
Q2 		$573K Sell
8,649
-948
-10% -$117K ﹤0.01% 2639
2017
Q1 		$2.08M Buy
9,597
+1,664
+21% +$238K ﹤0.01% 2187
2016
Q4 		$734K Sell
7,933
-94
-1% -$10.6K ﹤0.01% 2528
2016
Q3 		$1.09M Buy
8,027
+364
+5% +$36.2K ﹤0.01% 2389
2016
Q2 		$777K Sell
7,663
-783
-9% -$97.1K ﹤0.01% 2432
2016
Q1 		$1.38M Sell
8,446
-4,856
-37% -$984K ﹤0.01% 2215
2015
Q4 		$4.36M Buy
13,302
+691
+5% +$225K 0.01% 1614
2015
Q3 		$4.07M Buy
12,611
+477
+4% +$210K 0.01% 1608
2015
Q2 		$4.83M Buy
12,134
+5,249
+76% +$2.23M 0.01% 1562
2015
Q1 		$3.39M Buy
6,885
+849
+14% +$329K ﹤0.01% 1759
2014
Q4 		$2.16M Buy
6,036
+1,128
+23% +$336K ﹤0.01% 1965
2014
Q3 		$947K Buy
4,908
+102
+2% +$22.4K ﹤0.01% 2324
2014
Q2 		$1.15M Buy
4,806
+390
+9% +$79.3K ﹤0.01% 2256
2014
Q1 		$1.13M Buy
4,416
+442
+11% +$135K ﹤0.01% 2228
2013
Q4 		$788K Buy
3,974
+144
+4% +$25.6K ﹤0.01% 2390
2013
Q3 		$708K Buy
3,830
+194
+5% +$31.2K ﹤0.01% 2390
2013
Q2 		$660K Buy
+3,636
New +$515K ﹤0.01% 2383

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Charles Schwab's LUMO Position: Q2 2019 in Review

Charles Schwab sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2019, closing a stake of 5,411 shares — an estimated $94K sold.

Charles Schwab first reported a position in LUMO in Q2 2013 and held it in 24 quarters. The position peaked at $4.83M in Q2 2015. 68 funds tracked by Wall St. Rank hold LUMO as of Q2 2019.

  • Charles Schwab reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Charles Schwab sold 5,411 Lumos Pharma, Inc. Common Stock shares in Q2 2019, an estimated $94K.
  • Charles Schwab first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 24 quarters.
  • Charles Schwab's Lumos Pharma, Inc. Common Stock position peaked at $4.83M in Q2 2015.
  • 68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2019.

Based on Charles Schwab's 13F filing for Q2 2019, filed 9 Aug 2019.